Literature DB >> 9587405

Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.

M Iino1, D C Foster, W Kisiel.   

Abstract

Human blood coagulation factor VII has unique carbohydrate moieties O-glycosidically linked to serine 52 and serine 60 residues in its first epidermal growth factor-like domain. To study the functional role of these glycosyl moieties in factor VII, we constructed, expressed, and purified site-specific recombinant mutants of human factor VII in which serine 52 and serine 60 were conservatively replaced with alanine residues. S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids. The tissue factor-dependent and -independent amidolytic activities of these mutants were essentially indistinguishable from that of wild-type factor VIIa. In addition, equilibrium dialysis experiments indicated that the profiles of 45Ca2+ binding to these mutants were identical with that of wild-type factor VII. In the presence of either Ca2+ or EGTA, the Kd values for the interaction of the three factor VIIa mutants to full-length tissue factor were 2- to 5-fold higher than that of wild-type factor VIIa, while the Kd values for the interaction of these mutants to soluble tissue factor were 4- to 15-fold higher than that of wild-type factor VIIa. Measurement of the association and dissociation rate constants for factor VIIa binding to relipidated tissue factor apoprotein revealed that the association rate constants of the three factor VII mutants were decreased in comparison with that of wild-type factor VIIa, while the dissociation rate constants of these three mutants were virtually identical to that of wild-type factor VIIa. These findings strongly suggest that glycosyl moieties attached to Ser-52 and Ser-60 in factor VII/VIIa provide unique structural elements that are important for the rapid association of factor VII/VIIa with its cellular receptor and cofactor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9587405     DOI: 10.1006/abbi.1998.0595

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association.

Authors:  L Perera; T A Darden; L G Pedersen
Journal:  Biophys J       Date:  1999-07       Impact factor: 4.033

Review 2.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

3.  Group D prothrombin activators from snake venom are structural homologues of mammalian blood coagulation factor Xa.

Authors:  Veena S Rao; Jeremiah S Joseph; R Manjunatha Kini
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

4.  Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII.

Authors:  François Fenaille; Catherine Groseil; Christine Ramon; Sandrine Riandé; Laurent Siret; Sami Chtourou; Nicolas Bihoreau
Journal:  Glycoconj J       Date:  2008-07-20       Impact factor: 2.916

Review 5.  Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases.

Authors:  Peter Goettig
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

6.  Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.

Authors:  Ernst Böhm; Birgit K Seyfried; Michael Dockal; Michael Graninger; Meinhard Hasslacher; Marianne Neurath; Christian Konetschny; Peter Matthiessen; Artur Mitterer; Friedrich Scheiflinger
Journal:  BMC Biotechnol       Date:  2015-09-18       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.